Report Company Directory

AIKCHOL HOSPITAL PUBLIC COMPANY LIMITED

AIKIDO PHARMA INC.

• InsiderInsights.com Daily Ratings Report: May 31, 2024 by InsiderInsights.com
• InsiderInsights Weekly Report: May 4, 2024 by InsiderInsights.com
• InsiderInsights Weekly Report: April 20, 2024 by InsiderInsights.com
• InsiderInsights Weekly Report: April 13, 2024 by InsiderInsights.com
• InsiderInsights.com Daily Ratings Report: April 10, 2024 by InsiderInsights.com
• InsiderInsights.com Daily Ratings Report: April 8, 2024 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: December 14, 2022 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: December 13, 2022 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: December 12, 2022 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: September 19, 2022 by InsiderInsights.com

Aiko Corp.

• China Solar Industry "Positive catalyst could ease concerns on solar demand" Yan by UBS AG
• China Solar Industry "China Solar Weekly – Demand remains weak and limited ..." by UBS AG
• First Read: China Solar Industry "2021 SNEC Takeaway – New technology ..." by UBS AG
• First Read: China Solar Industry "2021 SNEC Takeaway – New technology ..." by UBS AG
• China Solar Industry "China Solar Weekly – Demand remains weak and limited ..." by UBS AG
• First Read: China Solar Industry "2021 SNEC Takeaway ... (Chinese Version)" by UBS AG
• China Solar Industry "China Solar Weekly – Demand remains ... (Chinese Version)" by UBS AG
• China Solar Industry "China Solar Weekly – Price forecast for supply chain ..." by UBS AG
• China Solar Industry "China Solar Weekly – More certainties on demand side ..." by UBS AG
• China Solar Industry "China Solar Weekly – Cost pass-through along the ..." by UBS AG

AIKYAM INTELLECTUAL PPTY CONS LTD

Aileron Therapeutics

• Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights by GlobeNewsWire
• Aileron Therapeutics to Present at Two Upcoming Investor Conferences by GlobeNewsWire
• Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million by GlobeNewsWire
• Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million by GlobeNewsWire
• Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) by GlobeNewsWire
• Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update by GlobeNewsWire
• Aileron Therapeutics Announces CEO Transition by GlobeNewsWire
• Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event by GlobeNewsWire
• Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 by GlobeNewsWire
• Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives by GlobeNewsWire